ImmunityBio Acquisition | Healthcare Deal in WA

ImmunityBio has completed the acquisition of ImmunityBio, a healthcare services other business in Washington, for $X. ImmunityBio is a commercial-stage immunotherapy company focused on intravesical BCG for high-grade non-muscle invasive bladder cancer, including the Tokyo-172 BCG strain. The company seeks to expand BCG supply in the U.S. through an exclusive U.S. development and supply agreement tied to Japan BCG Laboratory’s Tokyo strain, supported by a positive Phase III SWOG S1602 readout showing non-inferior efficacy versus TICE BCG. This healthcare M&A, categorized as other acquisition, is intended to position ImmunityBio as the sole U.S. biologics license application applicant for Tokyo-172 BCG and to support FDA engagement to address the long-running U.S. BCG shortage.